DE602005022089D1 - Sulfonylverbindungen als hemmer von 11-beta-hydroxysteroiddehydrogenase-1 - Google Patents
Sulfonylverbindungen als hemmer von 11-beta-hydroxysteroiddehydrogenase-1Info
- Publication number
- DE602005022089D1 DE602005022089D1 DE602005022089T DE602005022089T DE602005022089D1 DE 602005022089 D1 DE602005022089 D1 DE 602005022089D1 DE 602005022089 T DE602005022089 T DE 602005022089T DE 602005022089 T DE602005022089 T DE 602005022089T DE 602005022089 D1 DE602005022089 D1 DE 602005022089D1
- Authority
- DE
- Germany
- Prior art keywords
- inhibitors
- hydroxysteroiddehydrogenase
- beta
- sulfonyl compounds
- niddm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59936104P | 2004-08-06 | 2004-08-06 | |
PCT/US2005/027500 WO2006017542A1 (en) | 2004-08-06 | 2005-08-03 | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005022089D1 true DE602005022089D1 (de) | 2010-08-12 |
Family
ID=35839609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005022089T Active DE602005022089D1 (de) | 2004-08-06 | 2005-08-03 | Sulfonylverbindungen als hemmer von 11-beta-hydroxysteroiddehydrogenase-1 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7915252B2 (de) |
EP (1) | EP1797034B1 (de) |
JP (1) | JP2008509146A (de) |
CN (1) | CN1993320A (de) |
AT (1) | ATE472531T1 (de) |
AU (1) | AU2005271527B2 (de) |
CA (1) | CA2575736A1 (de) |
DE (1) | DE602005022089D1 (de) |
WO (1) | WO2006017542A1 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
EP2835367A1 (de) | 2005-01-05 | 2015-02-11 | AbbVie Inc. | Inhibitoren des 11-Beta-Hydroxysteroid-Dehydrogenase-1-Enzyms |
AU2006204017B2 (en) | 2005-01-05 | 2011-10-06 | Abbvie Inc. | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
AU2008241527B2 (en) | 2007-04-18 | 2014-02-13 | Merck Sharp & Dohme Llc | Triazole derivatives which are Smo antagonists |
RU2440989C2 (ru) | 2007-07-17 | 2012-01-27 | Ф.Хоффманн-Ля Рош Аг | ИНГИБИТОРЫ 11β-ГИДРОКСИСТЕРОИДНОЙ ДЕГИДРОГЕНАЗЫ |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
AP3592A (en) * | 2012-04-27 | 2016-02-15 | Novartis Ag | Cyclic bridgehead ether dgat1 inhibitors. |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
WO1998041519A1 (en) | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
KR20010021696A (ko) | 1997-07-11 | 2001-03-15 | 미즈노 마사루 | 퀴놀린 화합물 및 그의 의약용도 |
CA2334551A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
EP1187614A4 (de) | 1999-06-04 | 2005-06-22 | Merck & Co Inc | Substituierte piperidine als melanocortin-4 rezeptoragonisten |
TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
CN101898982B (zh) * | 1999-11-26 | 2012-07-04 | 盐野义制药株式会社 | Npy y5拮抗剂 |
JP2003527444A (ja) | 2000-03-23 | 2003-09-16 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体 |
EP1268449A4 (de) | 2000-03-23 | 2004-09-15 | Merck & Co Inc | Substituierte piperidine als melanokortin-rezeptor-agonisten |
PL364221A1 (en) | 2001-02-02 | 2004-12-13 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
DE60219295T2 (de) | 2001-02-28 | 2008-01-03 | Merck & Co., Inc. | Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten |
RU2281941C2 (ru) | 2001-03-22 | 2006-08-20 | Солвей Фармасьютикалс Б.В. | Производные 4,5-дигидро-1h-пиразола, обладающие cb1-антагонистической активностью |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP2005500308A (ja) | 2001-06-20 | 2005-01-06 | メルク エンド カムパニー インコーポレーテッド | 糖尿病を治療するためのジペプチジルペプチダーゼ阻害剤 |
CA2450579A1 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
IL158923A0 (en) | 2001-06-27 | 2004-05-12 | Smithkline Beecham Corp | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
CA2419888A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
JP4300108B2 (ja) | 2001-06-27 | 2009-07-22 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのピロリジン類 |
EP1404675B1 (de) | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
EP1615698B1 (de) | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | Neue amide derivate und deren pharmazeutische verwendungen |
EP1717225A4 (de) * | 2004-02-18 | 2009-10-21 | Kyorin Seiyaku Kk | Bicyclische amidderivate |
-
2005
- 2005-08-03 WO PCT/US2005/027500 patent/WO2006017542A1/en active Application Filing
- 2005-08-03 JP JP2007524932A patent/JP2008509146A/ja active Pending
- 2005-08-03 AT AT05777427T patent/ATE472531T1/de not_active IP Right Cessation
- 2005-08-03 CA CA002575736A patent/CA2575736A1/en not_active Abandoned
- 2005-08-03 CN CNA2005800265232A patent/CN1993320A/zh active Pending
- 2005-08-03 US US11/658,766 patent/US7915252B2/en active Active
- 2005-08-03 EP EP05777427A patent/EP1797034B1/de not_active Not-in-force
- 2005-08-03 DE DE602005022089T patent/DE602005022089D1/de active Active
- 2005-08-03 AU AU2005271527A patent/AU2005271527B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP1797034B1 (de) | 2010-06-30 |
AU2005271527B2 (en) | 2009-08-27 |
JP2008509146A (ja) | 2008-03-27 |
CN1993320A (zh) | 2007-07-04 |
EP1797034A1 (de) | 2007-06-20 |
US20080318930A1 (en) | 2008-12-25 |
ATE472531T1 (de) | 2010-07-15 |
EP1797034A4 (de) | 2009-07-15 |
WO2006017542A1 (en) | 2006-02-16 |
AU2005271527A1 (en) | 2006-02-16 |
US7915252B2 (en) | 2011-03-29 |
CA2575736A1 (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE472531T1 (de) | Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1 | |
ATE476425T1 (de) | Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1 | |
WO2007047625A3 (en) | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | |
JO2397B1 (en) | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors | |
CY1110753T1 (el) | Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i | |
WO2007087150A3 (en) | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | |
DE602007007614D1 (de) | Substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1 | |
DK2021337T3 (da) | Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1 | |
ATE471311T1 (de) | Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1 | |
DK2049513T3 (da) | Piperidinylsubstituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1 | |
CA2534221A1 (en) | Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | |
DK1807072T3 (da) | Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1 | |
NO20080010L (no) | GPCR-agonister | |
DK2049475T3 (da) | Cyclohexyl-substituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroid dehydrogenase1 | |
EA200870460A1 (ru) | Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 | |
NO20050102L (no) | 11-beta-hydroksysteroid-dehydrogenase 1-inhibitorer som kan anvendes ved behandlingen av sukkersyke, overvekt og dyslipidemi | |
DK1711184T3 (da) | (3-Oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamid-derivater og beslægtede forbindelser som glycogenphosphorylaseinhibitorer til behandling af diabetes og fedme | |
CY1112483T1 (el) | Αγωνιστες gpcr πιπεριδινης | |
ATE557024T1 (de) | Piperidinverbindungen als gpcr-agonisten | |
EA201000562A1 (ru) | Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы | |
EA201000561A1 (ru) | Производные пиридина, пригодные в качестве активаторов глюкокиназы | |
TW200609228A (en) | Substituted n-acyl-2-aminothiazoles | |
DOP2003000658A (es) | Inhibidores de la 11-beta-hydroxiesteroide deshidrogenasa 1 para la elaboracion de tratamiento de la diabetes, obesidad y dislipidemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R081 | Change of applicant/patentee |
Ref document number: 1797034 Country of ref document: EP Owner name: SCHERING CORPORATION, US Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, US Effective date: 20121213 |
|
R082 | Change of representative |
Ref document number: 1797034 Country of ref document: EP Representative=s name: ABITZ & PARTNER, DE Effective date: 20121213 |